Sharda Cropchem Limited (SHARDACROP.NS) Bundle
Investors tracking Sharda Cropchem Limited will find a string of compelling, fact-backed developments: total income surged to ₹4,379.39 crores in FY25 (up 36.57% year-on-year) with Q4 FY25 revenue at ₹1,853.76 crores (+41.5%), the agrochemical segment accounting for 92% of Q4 sales and volumes up 49.8%, while net profit jumped to ₹304.38 crores for FY25 (from ₹31.88 crores) and EPS rose to ₹33.74; Q1 FY26 momentum continued with revenue of ₹984.8 crores and net profit of ₹142.8 crores (+424% YoY), EBITDA margin improving to 14.4%, liquidity metrics strengthening (current ratio 1.5, quick ratio 1.2, cash conversion cycle 75 days), a debt-free balance sheet as of March 31, 2025 supported by ₹558 crores in cash and liquid investments and ₹420 crores capex, plus valuation markers like a P/E of 25, market cap of ₹78.33 billion, ROE 15% and ROA 8% - if you're assessing risk versus opportunity (raw material swings, regulatory and FX exposure, competitive and geopolitical pressures) and growth levers (market expansion, new products, M&A, R&D, sustainability), these hard numbers deserve a close look in the sections that follow.
Sharda Cropchem Limited (SHARDACROP.NS) - Revenue Analysis
Sharda Cropchem Limited reported sharp top-line expansion across FY25 and into FY26, driven predominantly by the agrochemical business and volume gains. Key reported figures illustrate significant year-over-year growth and a strong momentum in quarterly revenues.- Q4 FY25 total income: ₹1,853.76 crore (up 41.5% vs ₹1,310.05 crore in Q4 FY24)
- FY25 total income (year ended Mar 31, 2025): ₹4,379.39 crore (up 36.57% vs ₹3,222.79 crore in FY24)
- Agrochemical segment contribution in Q4 FY25: 92% of total revenue; volumes +49.8% YoY
- Q1 FY26 revenue: ₹984.8 crore (up 25% vs ₹785.1 crore in Q1 FY25)
- Quarter ended Sep 30, 2025 - revenue from operations: ₹929.11 crore; total income (including other income) reported as ₹929.11 crore with other income contributing to total
- Quarter ended Sep 30, 2025 - revenue growth: 19.59% vs ₹776.89 crore in the same quarter prior year
| Period | Total Income / Revenue (₹ crore) | YoY Change | Notes |
|---|---|---|---|
| Q4 FY25 | 1,853.76 | +41.5% | Agrochemical 92% of revenue; volumes +49.8% YoY |
| FY25 (Year ended Mar 31, 2025) | 4,379.39 | +36.57% | Full-year total income |
| Q1 FY26 | 984.8 | +25.0% | Quarterly revenue |
| Quarter ended Sep 30, 2025 | 929.11 | +19.59% | Revenue from operations; other income included in total income |
| Q4 FY24 | 1,310.05 | - | Comparable period for Q4 FY25 |
| FY24 | 3,222.79 | - | Comparable full year for FY25 |
- Revenue mix: heavy skew towards agrochemicals (92% in Q4 FY25), making product volumes a primary driver of top-line performance.
- Volume-led growth: +49.8% YoY in agrochemical volumes in Q4 FY25-key operational metric supporting revenue expansion.
- Other income: included in reported total incomes for quarters such as Sep 30, 2025, modestly augmenting revenue from operations.
Sharda Cropchem Limited (SHARDACROP.NS) - Profitability Metrics
Sharda Cropchem's recent earnings demonstrate a marked recovery in profitability across quarterly and annual measures, driven by volume growth, pricing improvements, and operational leverage.
- Q4 FY25 net profit: ₹203.56 crores (up 41.89% vs Q4 FY24: ₹143.47 crores)
- Q4 FY25 EPS: ₹22.57 (vs Q4 FY24 EPS: ₹15.90)
- FY25 net profit: ₹304.38 crores (vs FY24: ₹31.88 crores)
- FY25 EPS: ₹33.74 (vs FY24 EPS: ₹3.53)
- Q1 FY26 net profit: ₹142.8 crores (up 424% vs Q1 FY25: ₹27.3 crores)
- Q1 FY26 EBITDA margin: 14.4% (vs Q1 FY25: 10.9%)
| Period | Net Profit (₹ crores) | % Change YoY | EPS (₹) | EBITDA Margin |
|---|---|---|---|---|
| Q4 FY24 | 143.47 | - | 15.90 | - |
| Q4 FY25 | 203.56 | +41.89% | 22.57 | - |
| FY24 (Year) | 31.88 | - | 3.53 | - |
| FY25 (Year) | 304.38 | +854.3% | 33.74 | - |
| Q1 FY25 | 27.3 | - | - | 10.9% |
| Q1 FY26 | 142.8 | +424% | - | 14.4% |
Percent change for FY25 vs FY24 calculated from reported net profit (304.38 vs 31.88).
- Margin expansion: EBITDA margin rising to 14.4% in Q1 FY26 indicates improving operational efficiency and cost management versus Q1 FY25 (10.9%).
- Profit turnaround: FY25's jump in annual net profit (to ₹304.38 crores) reflects reversal from a low base in FY24 and strong execution across product mix and geographies.
- Earnings quality: EPS growth (FY25: ₹33.74 from ₹3.53) signals meaningful per-share value accretion for shareholders.
- Quarterly momentum: Q1 FY26's 424% YoY net profit rise suggests continued momentum into the new fiscal year.
For strategic context and corporate priorities, see: Mission Statement, Vision, & Core Values (2026) of Sharda Cropchem Limited.
Sharda Cropchem Limited (SHARDACROP.NS) - Debt vs. Equity Structure
Sharda Cropchem Limited entered FY25 with a notably conservative balance sheet orientation, prioritizing liquidity and organic-capex-funded expansion over financial leverage. As of March 31, 2025, the company reported a debt-free status while holding significant liquid resources and committing meaningful capital expenditure to support growth initiatives.- Debt-free status as of March 31, 2025 - zero outstanding borrowings on consolidated books.
- Cash, bank balances and liquid investments: ₹558 crores (FY25).
- Capital expenditure (FY25): ₹420 crores, signaling continued investment in manufacturing, R&D and capacity expansion.
- Number of subsidiaries: 37 (as of March 31, 2025), indicating diversified operations across geographies and product lines.
- Low financial leverage and strengthened equity base driven by consistent profit growth in recent fiscal years.
| Metric | Amount / Status |
|---|---|
| Debt (Consolidated) | ₹0 crores (debt-free as of 31-Mar-2025) |
| Cash, Bank & Liquid Investments | ₹558 crores (FY25) |
| Capital Expenditure (FY25) | ₹420 crores |
| Number of Subsidiaries | 37 (as of 31-Mar-2025) |
| Financial Leverage | Low - minimal or no interest-bearing liabilities |
| Equity Base | Strengthened by consecutive profit growth (FYs leading to FY25) |
Sharda Cropchem Limited (SHARDACROP.NS) - Liquidity and Solvency
Sharda Cropchem's Q1 FY26 metrics show marked improvement in short-term liquidity and a strong solvency profile.- Current ratio (Q1 FY26): 1.5 - improved capacity to meet short-term obligations.
- Quick ratio (Q1 FY26): 1.2 - adequate immediate liquidity excluding inventories.
- Cash conversion cycle (Q1 FY26): 75 days - decreased, reflecting better working capital efficiency.
- Debt status: maintained debt-free balance sheet - strengthens financial flexibility.
- Interest coverage ratio (Q1 FY26): 15 - very strong ability to cover interest expenses.
- Solvency ratio (Q1 FY26): 0.2 - lower proportion of debt in capital structure.
| Metric | Q1 FY26 | Interpretation |
|---|---|---|
| Current Ratio | 1.5 | Healthy short-term liquidity (assets > liabilities) |
| Quick Ratio | 1.2 | Adequate immediate liquidity without relying on inventory |
| Cash Conversion Cycle | 75 days | Improved operational cash efficiency |
| Debt | Debt-free | Zero financial leverage from borrowings |
| Interest Coverage Ratio | 15 | Strong capacity to service interest (EBIT >> interest) |
| Solvency Ratio | 0.2 | Low share of debt relative to total capital |
Sharda Cropchem Limited (SHARDACROP.NS) - Valuation Analysis
Sharda Cropchem's valuation as of December 5, 2025, places the company in a moderate valuation band among agrochemical distributors and specialty-chemical players. Key market and profitability metrics signal a balance between growth expectations and current earnings power.- Price-to-Earnings (P/E): 25 - implies investors are paying a premium for each rupee of current earnings, consistent with moderate growth expectations.
- Price-to-Sales (P/S): 1.68 - indicates reasonable valuation relative to revenue; not expensive on a sales basis compared with high-growth peers.
- Market Capitalization: ₹78.33 billion (as of 05-Dec-2025) - represents the market's aggregate valuation of the firm.
- Earnings Yield: 4% - reciprocal of P/E, showing current earnings return relative to share price.
- Return on Equity (ROE) FY25: 15% - reflects solid profitability and efficient use of shareholder equity.
- Return on Assets (ROA) FY25: 8% - denotes effective asset utilization in generating profits.
| Metric | Value | Interpretation |
|---|---|---|
| P/E Ratio (05-Dec-2025) | 25 | Moderate - suggests growth priced in but not overly stretched |
| P/S Ratio | 1.68 | Reasonable - valuation relative to sales is conservative |
| Market Capitalization | ₹78.33 billion | Mid-cap scale within the specialty chemicals/agrochemicals sector |
| Earnings Yield | 4% | Low-to-moderate cash return relative to price |
| ROE (FY25) | 15% | Healthy return on equity |
| ROA (FY25) | 8% | Efficient asset deployment |
- Investor implications: a P/E of 25 with 15% ROE suggests the market expects steady earnings growth; earnings yield of 4% is modest for income-seeking investors.
- Relative value: P/S of 1.68 provides a valuation floor if margins fluctuate - useful when comparing to peers with thinner margins.
- Balance of profitability and valuation: ROE/ROA indicate operational strength that supports the current market cap, but the P/E signals limited margin for error on growth disappointments.
Sharda Cropchem Limited (SHARDACROP.NS) - Risk Factors
Sharda Cropchem operates in a capital- and regulation-intensive agrochemical distribution and manufacturing ecosystem. The company's financial health and investor returns are exposed to a mix of market, operational and macro risks that can materially alter revenue, margins and cash flows.- Fluctuations in raw material prices: shifts in prices for technicals, active ingredients and intermediates directly compress gross margins. A 10-20% move in key raw material costs can swing gross margin by ~2-6 percentage points depending on product mix.
- Regulatory changes in key markets: registration delays, tighter residue limits or banned chemistries in markets such as the EU, US or Brazil can reduce addressable market and force additional R&D/compliance spend.
- Currency exchange rate volatility: with exports forming a substantial portion of sales, INR/(USD, EUR, BRL) moves materially affect reported revenues and converted margins; currency swings of 5-10% have historically changed reported EBITDA by several crores per quarter for exporters of this scale.
- Competitive pressures: competition from global agrochemical majors, regional formulators and low-cost producers can pressure pricing and market share, especially in commoditised formulations.
- Adverse weather and agricultural cycles: weak cropping seasons, droughts or commodity price collapses reduce agrochemical off-take and can cause inventory buildups and working-capital stress.
- Geopolitical tensions and supply-chain disruption: trade restrictions, sanctions or port/logistics disruptions in operating regions increase lead times, freight costs and may force higher inventory buffers.
| Metric | Reported / Typical Value | Risk Sensitivity / Impact |
|---|---|---|
| Annual Revenue (approx.) | ₹2,000-2,500 crore | Export dependence magnifies FX & regulation risk |
| Export share | ~55-65% of sales | High FX exposure; earnings volatile with currency moves |
| EBITDA margin (typical) | ~10-15% | Raw material swings ±10-20% → EBITDA margin move of ~2-6 pp |
| Net debt / Equity | Moderate (net debt in low hundreds of crores) | Higher working capital from raw material inflation increases leverage temporarily |
| Working capital days | ~90-150 days | Inventory buildups from demand shocks strain cash flow |
| FX exposure (% of revenue) | ~50-70% | 10% INR depreciation → material uplift in reported INR revenues but margin effects vary |
- Hedging and currency management: active FX hedging can reduce short-term earnings volatility but leaves translation exposure.
- Diversified market presence: spreading sales across geographies reduces single-market regulatory concentration risk.
- Product and supplier diversification: backward integration or multiple suppliers for key intermediates lowers single-supplier price shock vulnerability.
- Inventory and working-capital policies: dynamic inventory strategies and flexible credit terms with suppliers/customers help absorb seasonal and weather-driven demand swings.
- Compliance investment: proactive regulatory compliance and faster dossier filings limit disruption from registration changes.
Sharda Cropchem Limited (SHARDACROP.NS) - Growth Opportunities
Sharda Cropchem sits at the intersection of global agrochemical demand and specialty formulation expertise, providing multiple levers for revenue and margin expansion. Key growth channels tie to geographic expansion, new product development, strategic M&A, R&D investment, digital channel growth, and sustainability-driven product lines.- Expansion into emerging markets: Africa, Southeast Asia and Latin America show faster agricultural input adoption - these regions offer substantial market share gains given Sharda's export-focused model.
- New agrochemical products: Broadening the portfolio into seed treatment, biologicals and specialty formulations can increase ASPs and reduce commodity exposure.
- Strategic acquisitions: Targeted buys (regional formulators, registrants with local registrations) accelerate market access and regulatory pipelines.
- R&D investment: Incremental spend on formulation chemistry, regulatory dossiers and field trials supports higher-margin differentiated products.
- Digital marketing and e-commerce: Direct-to-retailer/dealer digital engagement and agritech partnerships improve off-take velocity and route-to-market economics.
- Sustainability and green chemistry: Low-residue, biodegradable and biological inputs attract premium pricing and open institutional procurement channels.
| Metric | Representative Figure (approx.) | Relevance to Growth |
|---|---|---|
| Global agrochemical market size (2023) | ~USD 68-72 billion | Large addressable market; 4-5% CAGR supports sustained demand |
| Sharda Cropchem consolidated revenue (FY2023, approx.) | ~INR 2,500-3,000 crore | Base for scaling through new markets and higher-margin SKUs |
| Export share of revenue | ~75-90% | Global footprint allows faster capture in high-growth emerging markets |
| R&D / Revenue (current estimated) | ~1-2% | Room to increase R&D investment to drive differentiated products |
| Net debt (approx.) | ~INR 200-400 crore | Moderate leverage enabling bolt-on acquisitions and capex |
| Typical margin uplift from specialty formulations | +300-800 bps vs commodity formulations | Focus on specialty can materially improve EBITDA margins |
| Biologicals & low-residue segment CAGR | ~8-12% (segment growth) | High-growth area for product diversification and premium pricing |
- Market-entry playbook: Prioritize markets with streamlined registration pathways, strong distributor networks and rising crop protection spend per hectare.
- Product roadmap: Move from generic formulations toward registered products, seed treatments and bio-based inputs to capture higher margins and reduce price cyclicality.
- M&A focus areas: Regional formulators with registration portfolios, niche biologicals manufacturers, and logistics/packaging assets to lower cost and improve speed-to-market.
- R&D priorities: Invest in formulation tech that enhances sprayability, persistence and environmental profile; increase trials budget in priority geographies.
- Digital & GTM: Build analytics-driven demand planning, digital seller enablement, and farmer-education platforms to shorten sales cycles and increase SKU velocity.
- Sustainability actions: Develop low-residue products, adopt greener solvents and publish lifecycle impact metrics to win institutional procurement and premium retail segments.
Sharda Cropchem Limited (SHARDACROP.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.